Expert Review of Clinical Immunology,
Journal Year:
2023,
Volume and Issue:
19(7), P. 745 - 769
Published: May 1, 2023
Allergy,
the
immunological
hypersensitivity
to
innocuous
environmental
compounds,
is
a
global
health
problem.
The
disease
triggers,
allergens,
are
mostly
proteins
contained
in
various
natural
sources
such
as
plant
pollen,
animal
dander,
dust
mites,
foods,
fungi,
and
insect
venoms.
Allergies
can
manifest
with
wide
range
of
symptoms
organs
be
anything
from
just
tedious
life-threatening.
A
majority
all
allergy
patients
self-treated
symptom-relieving
medicines,
while
allergen
immunotherapy
(AIT)
only
causative
treatment
option.This
review
will
aim
give
an
overview
state-of-the-art
management,
including
use
new
biologics
application
biomarkers,
special
emphasis
discussion
on
current
research
trends
field
AIT.Conventional
AIT
has
proven
effective,
but
years-long
compromises
patient
compliance.
Moreover,
typically
not
offered
for
food
allergies.
Hence,
there
need
new,
safe
methods.
Novel
routes
administration
(e.g.
oral
intralymphatic),
hypoallergenic
products,
more
effective
adjuvants
hold
great
promise.
Most
recently,
development
allergen-specific
monoclonal
antibodies
passive
may
also
allow
currently
treated
or
treatable.
Cancer Cell International,
Journal Year:
2022,
Volume and Issue:
22(1)
Published: Aug. 13, 2022
The
primary
purpose
of
ADCs
is
to
increase
the
efficacy
anticancer
medications
by
minimizing
systemic
drug
distribution
and
targeting
specific
cells.
Antibody
conjugates
(ADCs)
have
changed
way
cancer
treated.
However,
because
only
a
tiny
fraction
patients
experienced
long-term
advantages,
current
preclinical
clinical
research
has
been
focused
on
combination
trials.
complex
interaction
with
tumor
its
microenvironment
appear
be
reliant
certain
ADC,
all
which
significant
therapeutic
consequences.
Several
trials
in
various
types
are
now
underway
examine
potential
ADC
therapy,
based
encouraging
results.
This
review
tackles
use
emphasizing
essential
processes
underlying
their
positive
impacts
solid
hematological
malignancies.
Additionally,
opportunities
explored
understand
mechanisms
action,
mechanism
resistance
against
ADCs,
how
overcome
following
administration.
Recent
findings
aroused
interest,
leading
large
number
rationale
behind
as
well
features
recent
breakthroughs,
will
discussed.
We
then
offer
an
approach
for
maximizing
value
that
can
bring
highlighting
key
ideas
distinct
strategies.
International Journal of Environmental Research and Public Health,
Journal Year:
2022,
Volume and Issue:
19(11), P. 6881 - 6881
Published: June 4, 2022
Colorectal
cancer
is
one
of
the
most
common
cancers
in
Europe
and
world.
Cancer
treatments
have
side
effects
cause
significant
deterioration
patient’s
nutritional
status.
Patient
malnutrition
may
worsen
health
condition
prevent
deliberate
therapy.
The
aim
this
review
was
to
describe
available
data
about
clinical
nutrition
colorectal
patients.
A
large
proportion
patients
suffer
from
malnutrition,
which
negatively
affects
survival
prognosis,
quality
life,
oncological
Therefore,
monitoring
status
during
treatment
essential
can
be
used
arrange
proper
therapy
enhance
patient
responses,
effects,
shorten
recovery
time.
principles
anticancer
should
mainly
consider
light
low-fat
foods,
exclusion
lactose
gluten-containing
foods
certain
cases,
or
introduction
special
dietary
products
such
as
oral
supplements
it
tailored
patients’
individual
needs.
Cancer Letters,
Journal Year:
2024,
Volume and Issue:
586, P. 216633 - 216633
Published: Jan. 26, 2024
Primary
cutaneous
melanoma
is
the
most
lethal
of
all
skin
neoplasms
and
its
incidence
increasing.
Clinical
management
advanced
in
last
decade
has
been
revolutionised
by
availability
immunotherapies
targeted
therapies,
used
alone
combination.
This
article
summarizes
advances
treatment
late-stage
including
use
protein
kinase
inhibitors,
antibody-based
immune
checkpoint
adoptive
immunotherapy,
vaccines
more
recently,
small
molecules
peptidomimetics
as
emerging
immunoregulatory
agents
lessen
toxicity
decrease
resistance
to
therapy.
Transplantation,
Journal Year:
2024,
Volume and Issue:
unknown
Published: April 1, 2024
Background.
Focal
segmental
glomerulosclerosis
(FSGS)
is
a
common
cause
of
end-stage
kidney
disease
and
frequently
recurs
after
transplantation.
Recurrent
FSGS
(rFSGS)
associated
with
poor
allograft
patient
outcomes.
Bleselumab,
fully
human
immunoglobulin
G4
anti-CD40
antagonistic
monoclonal
antibody,
disrupts
CD40−related
processes
in
FSGS,
potentially
preventing
rFSGS.
Methods.
A
phase
2a,
randomized,
multicenter,
open-label
study
adult
recipients
(aged
≥18
y)
living
or
deceased
donor
transplant
history
biopsy-proven
primary
FSGS.
The
assessed
the
efficacy
bleselumab
combined
tacrolimus
corticosteroids
as
maintenance
immunosuppression
prevention
rFSGS
>12
mo
posttransplantation,
versus
standard
care
(SOC)
comprising
tacrolimus,
mycophenolate
mofetil,
corticosteroids.
All
patients
received
basiliximab
induction.
endpoint
was
rFSGS,
defined
proteinuria
(protein-creatinine
ratio
≥3.0
g/g)
death,
graft
loss,
loss
to
follow-up
imputed
through
3
posttransplant.
Results.
Sixty-three
were
followed
for
12
posttransplantation.
Relative
decrease
occurrence
SOC
40.7%
(95%
confidence
interval,
−89.8
26.8;
P
=
0.37;
absolute
12.7%
[95%
−34.5
9.0]).
Central-blinded
biopsy
review
found
relative
(absolute)
decreases
10.9%
(3.9%),
17.0%
(6.2%),
20.5%
(7.5%)
at
3,
6,
posttransplant,
respectively;
these
differences
not
statistically
significant.
Adverse
events
similar
both
treatments.
No
deaths
occurred
during
study.
Conclusions.
In
at-risk
recipients,
numerically
reduced
SOC,
but
no
notable
difference
observed.
Brain,
Journal Year:
2024,
Volume and Issue:
147(6), P. 2053 - 2068
Published: May 13, 2024
Abstract
Aggregation
of
the
RNA-binding
protein
TAR
DNA
binding
(TDP-43)
is
a
hallmark
TDP-proteinopathies
including
amyotrophic
lateral
sclerosis
(ALS)
and
frontotemporal
dementia
(FTD).
As
TDP-43
aggregation
dysregulation
are
causative
neuronal
death,
there
special
interest
in
targeting
this
as
therapeutic
approach.
Previously,
we
found
that
extensively
co-aggregated
with
dual
function
GEF
(guanine
exchange
factor)
rho
guanine
nucleotide
factor
(RGNEF)
ALS
patients.
Here,
show
an
N-terminal
fragment
RGNEF
(NF242)
interacts
directly
RNA
recognition
motifs
competing
IPT/TIG
domain
NF242
essential
for
interaction.
Genetic
expression
fruit
fly
model
overexpressing
suppressed
neuropathological
phenotype
increasing
lifespan,
abolishing
motor
defects
preventing
neurodegeneration.
Intracerebroventricular
injections
AAV9/NF242
severe
murine
(rNLS8)
improved
lifespan
phenotype,
decreased
neuroinflammation
markers.
Our
results
demonstrate
innovative
way
to
target
proteinopathies
using
strong
affinity
aggregates
mechanism
includes
competition
sequestration,
suggesting
promising
strategy
such
FTD.
